Skip to main content

Tumor Necrosis Factor-Alpha Monoclonal Antibodies for Crohn's Disease: Tipping the Balance

Buy Article:

$55.00 plus tax (Refund Policy)

Crohn's disease (CD) is a chronic inflammatory disorder which may involve any part of gastrointestinal tract. Chronic inflammation is primarily due to an immunological imbalance between pro- and anti-inflammatory cytokines, and with a defective apoptosis of lamina propria T cells. Amongst the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) seems to play a central role in pathogenesis of CD.

Over the last years, increasing knowledge on the pathogenesis of CD together with progresses in bio-technology have led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, most importantly TNF-α and its receptors.

The aim of this paper is to critically review the rationale and state-of-the art for the use TNF-α inhibitors in the treatment of CD.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Certolizumab pegol; Infliximab; Lipopolysaccaride; T lymphocytes; TNF receptors; Toll-like receptors

Document Type: Research Article

Affiliations: Division of Gastroenterology,Istituto Clinico Humanitas-IRCCS in Gastroenterology, Viale Manzoni, Rozzano,Milan, Italy.

Publication date: 2007-06-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more